Aristeromycin, an adenosine analog, is an antibiotic and a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor[1][2]. S-adenosylhomocysteine hydrolase[1]
The IC50 value of Aristeromycin against AHCY is 38.5 nM at 50 μM S-adenosylhomocysteine (SAH) (approximately equal to the Km: 48 μM), but 271 nM at 1000 µM SAH (20× Km). With 60 min of preincubation, the mean IC50 value of Aristeromycin at 50 μM SAH is 12.7 nM[1].Aristeromycin has IC50 values of 3.2 μM for LNCaP-FGC cell growth and 0.88 μM for LNCaP-hr cell growth[1].At least in part, Aristeromycin can regulate oncogenic EZH2 expression by inducing miR-26a[1].
[1]. Uchiyama N, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146. [2]. Ishikura T, et al. Inhibition of S-adenosylhomocysteine hydrolase by purine nucleoside analogues. Nucleic Acids Symp Ser. 1983;(12):119-22.